ERBB2 and breast cancer: Trastuzumab has also been radiolabeled with a number of diagnostic and therapeutic radionuclides such as 64Cu or 68Ga 89Zr to non-invasively assess HER2 expression status in primary breast cancers, lymph node metastases and lung metastases [68].